Bristol Myers Squibb to open new cell therapy manufacturing facility in US
The new 244,000ft² cell therapy manufacturing facility is planned to be located on the company’s existing Devens campus
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
24 Feb 21
The new 244,000ft² cell therapy manufacturing facility is planned to be located on the company’s existing Devens campus
16 Feb 21
WHO’s Emergency Use Listing, granted to AstraZeneca and Serum Institute of India, will provide global access to the…
13 Jan 21
PBGI is focused on non-controlling equity investments in small- to medium-sized public and large-scale private companies developing clinical-stage…
30 Dec 20
If the discussions are fruitful, Moderna is expected to supply 40 million doses of mRNA-1273 vaccine in South…
16 Nov 20
Janssen will commit around $604m and BARDA nearly $454m to support the ongoing Phase 3 ENSEMBLE trial programme
22 Oct 20
Interim data from Phase ½ study demonstrates that the two candidate vaccines induced enhanced immune response and are…
14 Oct 20
The financing is part of the World Bank Group’s $160bn package to help developing countries fight the Covid-19…
13 Oct 20
The trials affected by the event include the phase 3 ENSEMBLE trial for JNJ-78436735
21 Jul 20
The Covid-19 vaccine is currently under development and the agreement with the UK government is subject to clinical…
17 Jul 20
J&J is preparing to start human trials of its Covid-19 vaccine this month and is working to accelerate…